 |
|
| Blog results | Results 1 - 10 of about 4,373 for bristol generic myers plavix. (0.21 seconds) |
| Sorted by relevance Sort by date |
| 6 Apr 2009 The FTC warned BMS that it would not approve a settlement of the Plavix litigation if BMS agreed not to launch its own generic version of Plavix that would compete against Apotex for generic sales. Notwithstanding these warnings, Bodnar ... Antitrust Division: Press Releases - http://www.usdoj.gov/atr/public/press_releases/2009/index09.htm |
| 19 Nov 2009 Plavix, developed jointly by Bristol-Myers Squibb (BMY) and Sanofi-Aventis (SNY), has been one of the best-selling drugs in the world since it hit the market 11 years ago, bringing in $4.5 billion in the first nine months of 2009. ... considering the amount of time left on the Plavix patent. He adds that both drugs should find their niche, but will likely not reach blockbuster status due to the competition from generic Plavix when that becomes available. ... Minyanville - http://www.minyanville.com/ |
| 18 Nov 2009 by c.morrison@elsevier.com (Chris Morrison) First, the news: FDA has revised Plavix labeling to emphasise that the Bristol-Myers Squibb/Sanofi Aventis blockbuster doesn't work too well in patients who are poor metabolizers of the drug. In particular, FDA is concerned about ... But what Medco wants above all is to carve out a long term market for generic clopidogrel--and in effect limit Effient's share (as well as the share of all future brands in the class)--to whatever slice can't be held for the generic. ... The IN VIVO Blog - http://invivoblog.blogspot.com/ - References [ More results from The IN VIVO Blog ] |
| 16 Nov 2009 James Cornelius is spinning off Mead Johnson so he can focus the drugmaker on its core business. Bristol is racing against the clock as a top-selling drug faces generic competition in 2012. ... There's an urgency because the company's big blood-thinner drug Plavix faces generic competition in 2012. “This marks the latest step in our company's transformation into a bio-pharma leader,” Cornelius says in a statement. When Cornelius was named interim CEO three years ago, ... Portfolio.com all articles - http://www.portfolio.com/ |
| 19 Nov 2009 by Melly Alazraki For the study's 8430 sickest patients, those taking the drug suffered fewer serious cardiovascular events (or deaths) than those taking Plavix, from Bristol-Myers Squibb (BMY) and Sanofi-Aventis (SNY). ... suggest an impact on lung function , and an unexplained lack of benefit over Plavix in U.S. patients, perhaps due to higher aspirin intake. Generic Concerns And generic competition on AstraZeneca's high-margin products, having already hurt sales, will likely increase. ... DailyFinance - http://www.dailyfinance.com/2009/06/05/job-losses-slow-in-may-but-unemployment-hit... [ More results from DailyFinance ] |
| 3 Nov 2009 Bloomberg -- Bristol-Myers Squibb Co. and Sanofi- Aventis SA won a U.S. Supreme Court fight over their $9.5 billion-a-year Plavix blood thinner as the justices refused to question a patent that bars generic versions until November 2011. ... BioSpace.com Featured News and Stories - http://www.biospace.com/ [ More results from BioSpace.com Featured News and Stories ] |
| 10 Nov 2009 by AP Bristol-Myers signs development deal with Alder. ... October 19th, 2009 Medco plans to compare Plavix, Effient in studyNEW YORK — Medco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world's second-best selling drug, with the newer Effient. FDA rejects expanded use of rheumatoid arthritis drug Rituxan. October 17th, 2009 FDA nixes wider use of rheumatoid arthritis drugThe Food and Drug Administration has rejected an application to expand ... Health News - http://blog.taragana.com/health/ [ More results from Health News ] |
| 18 Nov 2009 by Tracy Staton At a press conference yesterday, the FDA explained that it had analyzed new, unpublished data from Sanofi and concluded that Plavix's label needed changing. Luckily for Sanofi and its Plavix partner Bristol-Myers Squibb, ... ALSO: The generics arm of Swiss pharmaceutical company Novartis has launched an authorized generic version of Takeda's Prevacid, a gastroesophageal reflux disease drug. Report. Related Articles: Cardiologists warn on Plavix plus PPI ... News - http://www.fiercepharma.com/news [ More results from News ] |
| 16 Nov 2009 by G.T.Yeoh Cornelius has been selling assets to raise money for acquisitions and cutting jobs to lower costs by $2.5 billion by 2012, when the blood-thinner Plavix faces generic competition. “Mead Johnson's stock has been behaving like a rocket ... All About Work & Financial - http://guanteik.blogspot.com/ |
| 21 Oct 2009 "In this particular case, because Plavix will go generic in two years, should the study show that the effectiveness of Plavix for extensive metabolizers is comparable to that of Effient, we can provide patients and physicians with a choice of being able ... Plavix, Bristol-Myers Squibb's best-selling product, with worldwide net sales of $1.5 billion last year, is a perfect candidate for Medco's Genetics for Generics program since it is going off-patent in November 2011. ... Pharmacogenomics Reporter from GenomeWeb News - http://www.genomeweb.com/newsletter/4 - References [ More results from Pharmacogenomics Reporter from GenomeWeb News ] |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
